A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection (OSAKA)

October 30, 2024 updated by: Astellas Pharma Inc

A Multicenter, Four Arm, Randomized, Open Label Clinical Study Investigating Optimized Dosing in a Prograf®-/Advagraf®-Based Immunosuppressive Regimen in Kidney Transplant Subjects (OSAKA Study)

To compare how well the new formulation of Tacrolimus® used once daily, in combination with other drugs helps prevent the rejection of a new kidney after transplantation compared to the twice daily dose of Tacrolimus

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
1252

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Buenos Aires, Argentina, C1425FAB
      • Cordoba, Argentina, X5016KEH
  • Austria
      • Innsbruck, Austria, A-6020
      • Linz, Austria, A-4010
      • Wien, Austria, A-1090
  • Belgium
      • Brussels, Belgium, 1200
      • Brussels, Belgium, 1070
      • Ghent, Belgium, 9000
      • Leuven, Belgium, 3000
  • Czechia
      • Brno, Czechia, 65691
      • Hradec Kravlove, Czechia, 50005
      • Ostrava, Czechia, 70852
      • Prague, Czechia, 14021
  • France
      • Angers Cedex 01, France, 49033
      • Bordeaux, France, 33076
      • Brest Cedex 2, France, 29609
      • Creteil Cedex, France, 94010
      • La Tronche, France, 38700
      • Le Kremlin Bicetre Cedex, France, 94275
      • Limoges Cedex 1, France, 87042
      • Lyon Cedex 3, France, 69437
      • Nantes, France, 44035
      • Nice Cedex, France, 06002
      • Paris Cedex, France, 75908
      • Paris Cedex 15, France, 75743
      • Paris Cedex 20, France, 75970
      • Rennes Cedex 9, France, 35033
      • St. Etienne, France, 42055
      • Strasbourg Cedex, France, 67091
      • Suresnes Cedex, France, 92151
      • Toulouse Cedex, France, 31054
      • Tours Cedex 9, France, 37044
      • Vandoeuvre, France, 54511
  • Germany
      • Aachen, Germany, 52074
      • Berlin, Germany, 13353
      • Essen, Germany, 45147
      • Frankfurt, Germany, 60590
      • Freiburg I. Br, Germany, 79106
      • Halle, Germany, 06120
      • Hamburg, Germany, 20251
      • Hannover, Germany, 30625
      • Jena, Germany, 07747
      • Kaiserslautern, Germany, 67655
      • Kiel, Germany, 24105
      • Leipzig, Germany, 04103
      • Munchen, Germany, 81675
      • Munster, Germany, 48149
      • Regensburg, Germany, 93042
      • Rostock, Germany, 18057
      • Tubingen, Germany, 72076
  • Greece
      • Athens, Greece, 11527
      • Thessaloniki, Greece, 54642
  • Hungary
      • Budapest, Hungary, 1082
      • Szeged, Hungary, 6720
  • Ireland
      • Dublin, Ireland
  • Italy
      • Ancona, Italy, 60020
      • Bologna, Italy, 40138
      • Milano, Italy, 20162
      • Padova, Italy, 35128
      • Roma, Italy, 00144
      • Siena, Italy, 53100
      • Treviso, Italy, 31100
  • Netherlands
      • Maastricht, Netherlands, 6202 AZ
  • Norway
      • Oslo, Norway, NO-0027
  • Poland
      • Bialystok, Poland, 15-540
      • Gdansk, Poland, 80-211
      • Lublin, Poland, 20-090
      • Poznan, Poland, 60-479
      • Warsaw, Poland, 022-006
      • Wroclaw, Poland, 50-419
  • Portugal
      • Lisboa, Portugal, 1069-639
      • Porto, Portugal, 4099-001
  • Romania
      • Bucharest, Romania, 022328
      • Cluj Napoca, Romania, 400006
  • Russian Federation
      • Moscow, Russian Federation, 123182
      • Moscow, Russian Federation, 129090
      • Omsk, Russian Federation, 644112
      • St. Petersburg, Russian Federation, 197110
      • Volgograd, Russian Federation, 404120
  • Slovakia
      • Banska Bysterica, Slovakia, 975 17
      • Kosice, Slovakia, 040 11
  • South Africa
      • Cape Town, South Africa, 7925
      • Johannesburg, South Africa, 2193
  • Spain
      • A Coruna, Spain, 15006
      • Albacete, Spain, 02006
      • Alicante, Spain, 03010
      • Barakaldo-Vizcaya, Spain, 48903
      • Barcelona, Spain, 08035
      • Barcelona, Spain, 08907
      • Cadiz, Spain, 11009
      • Granada, Spain, 18012
      • Madrid, Spain, 28046
      • Madrid, Spain, 28034
      • Madrid, Spain, 28007
      • Murcia, Spain, 30120
      • Oviedo, Spain, 33006
      • Palma de Mallorca, Spain, 07014
      • Pamplona, Spain, 31080
      • Salamanca, Spain, 37007
      • Sevilla, Spain, 41013
      • Valencia, Spain, 46017
      • Valencia, Spain, 46009
      • Zaragoza, Spain, 50009
  • Sweden
      • Stockholm, Sweden, S-14186
      • Uppsala, Sweden, S-75185
  • Switzerland
      • Zurich, Switzerland, 8091
  • United Kingdom
      • Birmingham, United Kingdom, B15 2TH
      • Glasgow, United Kingdom, G11 6NT
      • Leicester, United Kingdom, LE54PW
      • Manchester, United Kingdom, M13 9WL

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • End stage kidney disease and a suitable candidate for primary renal transplantation or re-transplantation (unless the graft was lost from rejection within 12 months)
  • Receiving a kidney transplant from a cadaveric or living (non HLA identical) donor with compatible ABO blood type
  • Female subject of childbearing potential must have a negative serum pregnancy test at enrollment and must agree to maintain effective birth control during the study

Exclusion Criteria:

  • Receiving or having previously received an organ transplant other than a kidney
  • Cold ischemia time of the donor kidney > 30 hours
  • Receiving a graft from a non-heart-beating donor other than of Maastricht category 3 (withdrawn of support awaiting cardiac arrest)
  • Significant liver disease, defined as having continuously elevated SGPT/ALT and/or SGOT/AST and/or total bilirubin levels ≥ 2 times the upper value of the normal range of the investigational site or is receiving a graft from a hepatitis C or B positive donor
  • Requiring initial sequential or parallel therapy with immunosuppressive antibody preparation(s)
  • Requiring ongoing dosing with a systemic immunosuppressive drug prior to transplantation.
  • Significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer
  • Pregnant woman or breast-feeding mother
  • Subject or donor known to be HIV positive
  • Known allergy or intolerance to tacrolimus, macrolide antibiotics, corticosteroids, basiliximab or mycophenolate mofetil or any of the product excipients
  • Diagnosis of new-onset malignancy prior to transplantation, with the exception of basocellular or squamous cell carcinoma of the skin which had been treated successfully
  • Currently participating in another clinical trial, and/or has taken an investigational drug within 28 days prior to enrollment
  • Any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may complicate communication with the investigator

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Prograf + MMF + Steroids
oral
Drug: Mycophenolate Mofetil
oral
Other Names:
  • MMF
Drug: Prograf®
oral
Other Names:
  • FK506
  • Tacrolimus
Drug: methylprednisolone / prednisone
oral
Other Names:
  • corticosteroids
Active Comparator: Advagraf (dose 1) + MMF + steroids
oral
Drug: Mycophenolate Mofetil
oral
Other Names:
  • MMF
Drug: Advagraf®
oral
Other Names:
  • MR4
  • FK506XL
  • Tacrolimus extended release
Drug: methylprednisolone / prednisone
oral
Other Names:
  • corticosteroids
Active Comparator: Advagraf (dose 2) + MMF + steroids
oral
Drug: Mycophenolate Mofetil
oral
Other Names:
  • MMF
Drug: Advagraf®
oral
Other Names:
  • MR4
  • FK506XL
  • Tacrolimus extended release
Drug: methylprednisolone / prednisone
oral
Other Names:
  • corticosteroids
Active Comparator: Advagraf + MMF + Basilixmab + steroids
oral
Drug: Mycophenolate Mofetil
oral
Other Names:
  • MMF
Drug: Advagraf®
oral
Other Names:
  • MR4
  • FK506XL
  • Tacrolimus extended release
Drug: methylprednisolone / prednisone
oral
Other Names:
  • corticosteroids
Drug: Simulect
oral
Other Names:
  • basiliximab

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Efficacy failure rate
Time Frame: 24 weeks
24 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Renal Function, acute rejection, Biopsy confirmed acute rejection
Time Frame: 24 weeks
24 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Astellas Pharma Inc

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Central Contact, Astellas Pharma Europe B.V.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 14, 2008

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 2, 2010

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 2, 2010

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 16, 2008

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 16, 2008

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 17, 2008

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 1, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 30, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • PMR-EC-1210
  • 2007-005376-13 (EudraCT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

IPD Sharing Time Frame

Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

IPD Sharing Access Criteria

Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings